Alison Watkins Buys 214 Shares of CSL (ASX:CSL) Stock

CSL Limited (ASX:CSL) insider Alison Watkins acquired 214 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The shares were acquired at an average cost of A$151.56 per share, with a total value of A$32,432.98.

CSL Price Performance

The company has a current ratio of 1.86, a quick ratio of 1.68 and a debt-to-equity ratio of 64.46. The company has a market capitalization of $77.43 billion, a price-to-earnings ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32.

CSL Announces Dividend

The business also recently disclosed a Interim dividend, which will be paid on Wednesday, April 8th. Investors of record on Wednesday, April 8th will be given a dividend of $1.837 per share. The ex-dividend date is Monday, March 9th. This represents a yield of 121.0%. CSL’s dividend payout ratio (DPR) is presently 50.38%.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.